{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:23:15Z","timestamp":1790166195820,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2011,4,12]],"date-time":"2011-04-12T00:00:00Z","timestamp":1302566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,4,12]],"date-time":"2011-04-12T00:00:00Z","timestamp":1302566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1038\/leu.2011.67","type":"journal-article","created":{"date-parts":[[2011,4,12]],"date-time":"2011-04-12T08:40:26Z","timestamp":1302597626000},"page":"1159-1167","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem\/progenitor cells"],"prefix":"10.1038","volume":"25","author":[{"given":"F","family":"Pellicano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"\u0160imara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G V","family":"Helgason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Copland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T L","family":"Holyoake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,4,12]]},"reference":[{"key":"BFleu201167_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD . Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290\u2013293.","journal-title":"Nature"},{"key":"BFleu201167_CR2","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D . Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science 1990; 247: 824\u2013830.","journal-title":"Science"},{"key":"BFleu201167_CR3","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","volume":"112","author":"BJ Druker","year":"2008","unstructured":"Druker BJ . Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112: 4808\u20134817.","journal-title":"Blood"},{"key":"BFleu201167_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1053\/shem.2003.50044","volume":"40","author":"T Hughes","year":"2003","unstructured":"Hughes T, Branford S . Molecular monitoring of chronic myeloid leukemia. Semin Hematol 2003; 40: 62\u201368.","journal-title":"Semin Hematol"},{"key":"BFleu201167_CR5","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","volume":"101","author":"R Bhatia","year":"2003","unstructured":"Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701\u20134707.","journal-title":"Blood"},{"key":"BFleu201167_CR6","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/blood.V112.11.194.194","volume":"112","author":"S Chu","year":"2008","unstructured":"Chu S, Allen L, Tinisha M, David S, Stephen F, Ravi B . Persistence of leukemia stem cells in chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib treatment for 5 years. Blood (ASH Annu Meet Abstr) 2008; 112: 194","journal-title":"Blood"},{"key":"BFleu201167_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Broggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129\u2013141.","journal-title":"Cancer Cell"},{"key":"BFleu201167_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL . Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399\u2013401.","journal-title":"Science"},{"key":"BFleu201167_CR9","first-page":"227","volume":"93","author":"C Nicaise","year":"2008","unstructured":"Nicaise C, Wang X, Roy A, Pfister M, Chen T-T, Bleickardt E et al. Dasatinib pharmacokinetics and exposure-response: relationships to efficacy and safety in patients with chronic myelogenous leukemia in chronic phase (CML-CP). Haematologica (EHA Annu Meet Abstr) 2008; 93: 227.","journal-title":"Haematologica"},{"key":"BFleu201167_CR10","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532\u20134539.","journal-title":"Blood"},{"key":"BFleu201167_CR11","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","volume":"109","author":"HG Jorgensen","year":"2007","unstructured":"Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL . Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007; 109: 4016\u20134019.","journal-title":"Blood"},{"key":"BFleu201167_CR12","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029\u20131035.","journal-title":"Lancet Oncol"},{"key":"BFleu201167_CR13","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1182\/blood.V98.13.3860","volume":"98","author":"C Gajate","year":"2001","unstructured":"Gajate C, Mollinedo F . The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of Fas\/CD95 into membrane rafts in human leukemic cells. Blood 2001; 98: 3860\u20133863.","journal-title":"Blood"},{"key":"BFleu201167_CR14","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1182\/blood-2007-09-112573","volume":"111","author":"M Copland","year":"2008","unstructured":"Copland M, Pellicano F, Richmond L, Allan EK, Hamilton A, Lee FY et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008; 111: 2843\u20132853.","journal-title":"Blood"},{"key":"BFleu201167_CR15","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1182\/blood-2009-05-219550","volume":"114","author":"F Pellicano","year":"2009","unstructured":"Pellicano F, Copland M, Jorgensen HG, Mountford J, Leber B, Holyoake TL . BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem\/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta. Blood 2009; 114: 4186\u20134196.","journal-title":"Blood"},{"key":"BFleu201167_CR16","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/sj.leu.2403785","volume":"19","author":"HG Jorgensen","year":"2005","unstructured":"Jorgensen HG, Allan EK, Graham SM, Godden JL, Richmond L, Elliott MA et al. Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia 2005; 19: 1184\u20131191.","journal-title":"Leukemia"},{"key":"BFleu201167_CR17","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1182\/blood-2006-09-045039","volume":"109","author":"TK Nguyen","year":"2007","unstructured":"Nguyen TK, Rahmani M, Harada H, Dent P, Grant S . MEK1\/2 inhibitors sensitize Bcr\/Abl+ human leukemia cells to the dual Abl\/Src inhibitor BMS-354\/825. Blood 2007; 109: 4006\u20134015.","journal-title":"Blood"},{"key":"BFleu201167_CR18","first-page":"188","volume":"62","author":"C Yu","year":"2002","unstructured":"Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P et al. Pharmacologic mitogen-activated protein\/extracellular signal-regulated kinase kinase\/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr\/Abl-expressing human leukemia cells. Cancer Res 2002; 62: 188\u2013199.","journal-title":"Cancer Res"},{"key":"BFleu201167_CR19","doi-asserted-by":"publisher","first-page":"5281","DOI":"10.1200\/JCO.2005.14.415","volume":"23","author":"PM Lorusso","year":"2005","unstructured":"Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005; 23: 5281\u20135293.","journal-title":"J Clin Oncol"},{"key":"BFleu201167_CR20","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1016\/j.bmcl.2008.10.054","volume":"18","author":"SD Barrett","year":"2008","unstructured":"Barrett SD, Bridges AJ, Dudley DT, Saltiel AR, Fergus JH, Flamme CM et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett 2008; 18: 6501\u20136504.","journal-title":"Bioorg Med Chem Lett"},{"key":"BFleu201167_CR21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319\u2013325.","journal-title":"Blood"},{"key":"BFleu201167_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27\u201355.","journal-title":"Adv Enzyme Regul"},{"key":"BFleu201167_CR23","doi-asserted-by":"publisher","first-page":"4572","DOI":"10.1074\/jbc.M209807200","volume":"278","author":"D Matallanas","year":"2003","unstructured":"Matallanas D, Arozarena I, Berciano MT, Aaronson DS, Pellicer A, Lafarga M et al. Differences on the inhibitory specificities of H-Ras, K-Ras, and N-Ras (N17) dominant negative mutants are related to their membrane microlocalization. J Biol Chem 2003; 278: 4572\u20134581.","journal-title":"J Biol Chem"},{"key":"BFleu201167_CR24","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/0092-8674(94)90133-3","volume":"77","author":"S Cowley","year":"1994","unstructured":"Cowley S, Paterson H, Kemp P, Marshall CJ . Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 1994; 77: 841\u2013852.","journal-title":"Cell"},{"key":"BFleu201167_CR25","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1038\/sj.onc.1203479","volume":"19","author":"PJ Coffer","year":"2000","unstructured":"Coffer PJ, Koenderman L, de Groot RP . The role of STATs in myeloid differentiation and leukemia. Oncogene 2000; 19: 2511\u20132522.","journal-title":"Oncogene"},{"key":"BFleu201167_CR26","doi-asserted-by":"publisher","first-page":"6643","DOI":"10.1038\/sj.onc.1204807","volume":"20","author":"Y Okutani","year":"2001","unstructured":"Okutani Y, Kitanaka A, Tanaka T, Kamano H, Ohnishi H, Kubota Y et al. Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway. Oncogene 2001; 20: 6643\u20136650.","journal-title":"Oncogene"},{"key":"BFleu201167_CR27","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1182\/blood-2004-02-0749","volume":"105","author":"KJ Aichberger","year":"2005","unstructured":"Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K et al. Identification of mcl-1 as a BCR\/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005; 105: 3303\u20133311.","journal-title":"Blood"},{"key":"BFleu201167_CR28","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/blood.V106.11.693.693","volume":"106","author":"M Copland","year":"2005","unstructured":"Copland M, Hamilton A, Allan EK, Brunton V, Holyoake TL . BMS-214662 targets quiescent chronic myeloid leukaemia stem cells and enhances the activity of both imatinib and dasatinib (BMS-354825). Blood (ASH Annu Meet Abstr) 2005; 106: 693.","journal-title":"Blood"},{"key":"BFleu201167_CR29","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","volume":"94","author":"T Holyoake","year":"1999","unstructured":"Holyoake T, Jiang X, Eaves C, Eaves A . Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999; 94: 2056\u20132064.","journal-title":"Blood"},{"key":"BFleu201167_CR30","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/sj.onc.1204142","volume":"20","author":"Y Fukuchi","year":"2001","unstructured":"Fukuchi Y, Kizaki M, Yamato K, Kawamura C, Umezawa A, Hata J et al. Mcl-1, an early-induction molecule, modulates activin A-induced apoptosis and differentiation of CML cells. Oncogene 2001; 20: 704\u2013713.","journal-title":"Oncogene"},{"key":"BFleu201167_CR31","first-page":"2118","volume":"63","author":"C Yu","year":"2003","unstructured":"Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D et al. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr\/Abl+ human myeloid leukemia cells. Cancer Res 2003; 63: 2118\u20132126.","journal-title":"Cancer Res"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201167","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T14:12:10Z","timestamp":1648735930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,12]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["BFleu201167"],"URL":"https:\/\/doi.org\/10.1038\/leu.2011.67","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,12]]},"assertion":[{"value":"17 June 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TLH receives per year approximately $10\u2009000 combined from consultancy, speaking fees, honoraria and service on advisory boards from Bristol\u2013Myers Squibb and Novartis. TLH also received research funding from Bristol-Myers Squibb. MC has undertaken consultancy work for Bristol\u2013Myers Squibb and is on its Advisory Board and has received honoraria from both Bristol\u2013Myers Squibb and Novartis within the last 2 years. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}